급성 호흡곤란 증후군(ARDS) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

Thelansis's "Acute Respiratory Distress Syndrome (ARDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Respiratory Distress Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening inflammatory lung condition characterized by acute, non-cardiogenic pulmonary edema resulting from disruption of the alveolar-capillary barrier. This leads to diffuse alveolar damage (DAD), impaired gas exchange, and refractory hypoxemia.

ARDS typically arises as a complication of direct pulmonary insults (e.g., severe pneumonia, aspiration) or indirect systemic conditions such as Sepsis and major trauma. The pathophysiology is driven by an uncontrolled inflammatory cascade, leading to increased vascular permeability, alveolar flooding, and loss of lung compliance.

Diagnosis and severity classification are based on the Berlin Definition, which stratifies ARDS into mild, moderate, and severe categories according to the degree of hypoxemia (PaO2/FiO2 ratio) and the presence of bilateral infiltrates not explained by cardiac failure or fluid overload.

There are currently no approved targeted pharmacological therapies for ARDS, and management remains entirely supportive. Standard of care relies on lung-protective mechanical ventilation strategies (low tidal volume, optimized PEEP), conservative fluid management, and prevention of ventilator-induced lung injury (VILI). In severe cases, advanced interventions such as prone positioning, neuromuscular blockade, and venovenous extracorporeal membrane oxygenation (VV-ECMO) are utilized to improve oxygenation and survival outcomes.

Key Highlights

• In the US, incident ARDS cases are projected to increase from 547.3K in 2025 to 586.7K by 2035, reflecting a modest growth trajectory (0.7% CAGR) linked to aging population and rising critical illness incidence.
• Despite high incidence, treatment remains entirely supportive, with no approved disease-modifying therapies, representing a major unmet clinical need.
• Increasing research focus on anti-inflammatory, endothelial-stabilizing, and regenerative therapies is expected to shape future treatment paradigms.

Market Overview

• The ARDS market in Italy is projected to grow from $62M in 2025 to $122M by 2035, reflecting moderate-to-strong growth driven by critical care advancements and supportive therapy utilization.
• Market growth is not directly correlated with incidence alone but influenced by:
• Increased use of advanced ICU interventions (e.g., ECMO, ventilation technologies)
• Rising healthcare expenditure in critical care settings
• Current market value is largely derived from supportive care infrastructure (ventilation systems, ICU management), rather than pharmacological therapies.
• Future market expansion will depend on the development and adoption of targeted therapies addressing the underlying inflammatory and vascular mechanisms of ARDS.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Changchun Tuohua Pharmaceutical Co., Ltd.
• Breathe Biologics, Inc.
• Staidson (Beijing) Biopharmaceuticals Co., Ltd.
• EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
• HTIC, Inc
• BioAegis Therapeutics Inc.
• Direct Biologics, LLC
• Implicit Bioscience
• Dompe Farmaceutici S.p.A
• Pharmazz, Inc.
• Aqualung Therapeutics Corp.
• Arch Biopartners Inc.
• Vasomune Therapeutics, Inc.
• ImmunityBio, Inc.
• AVM Biotechnology Inc

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)